Marc LePage, president and CEO of Genome Canada describes the early days of the organization and talks modern day plans, such as personalized diagnostics for rare diseases, international alliances and genomic data collection and sharing.
Marc, you helped pioneer the creation of Genome in 2000 and led Génome Québec for many years before heading Genome Canada. What were the highlights of Genome Canada’s development?
Our model is based on leveraging the federal investment with co-funding from multiple sources
